Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Pfizer

Stock Market Gains As Consumer Confidence Rises; Techs Rise; Vaccine Stocks Pop

The stock market gained as consumer confidence rose, peace talks resumed between Russia and Ukraine and vaccine stocks popped.

Investors Business Daily

US FDA approves second Covid booster for Americans 50 and older

Immunocompromised people also eligible for second booster, with CDC now to decide how and when such doses are offered

The Guardian - US

FDA clears way for millions to get additional COVID-19 boosters

U.S. regulators cleared second booster doses of COVID-19 vaccine from Moderna Inc. and the partnership of Pfizer Inc. and BioNTech SE for adults 50 and older, making millions more people eligible for the shots as concern grows about a potential new wave of infections.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

FDA clears way for millions to get additional COVID-19 boosters

Tribune News Service

FDA approves another COVID booster for 50 and up

The Food and Drug Administration’s decision opens a fourth dose of the Pfizer or Moderna vaccines to those people at least four months after their previous booster.

Chicago Sun-Times

Pfizer, Moderna Win FDA Approval of Fourth Covid Shot

The FDA has approved a fourth shot of Covid vaccines made by Pfizer and Moderna.

The Street

FDA approves another Pfizer, Moderna Covid booster for 50 and up

US regulators are allowing people 50 and older to get another booster dose of the Pfizer or Moderna Covid-19 vaccine

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

CDC recommends second booster shot for Americans over 50

The plan is an effort to protect older Americans if there is another surge in infections.

Axios

Pfizer's Second Etrasimod Phase 3 Ulcerative Colitis Trial Hits Primary Goal

Pfizer Inc (NYSE:PFE) has announced topline results from a second Phase 3 study of etrasimod for moderately to severely active ulcerative colitis (UC). The 12- and 52-week ELEVATE UC 52 follow the recent announcement of 12-week findings from the ELEVATE UC 12 trial. In this 52-week study, also known as ELEVATE UC 52,…

Benzinga

Biden and allies vow to keep up Russia punishment for ‘brutal attacks in Ukraine’ – as it happened

US and European leaders pledge assistance for people inside Ukraine and for those fleeing country

The Guardian - US

Pfizer's COVID-19 Oral Therapy To Be Tested In Hospitalized COVID-19 Patients In UK: Reuters

Pfizer Inc's (NYSE: PFE) oral COVID-19 therapy will be evaluated as a potential treatment for hospitalized COVID-19 patients in a major British trial.

Benzinga

Check Out What Whales Are Doing With PFE

A whale with a lot of money to spend has taken a noticeably bearish stance on Pfizer. Looking at options history for Pfizer (NYSE:PFE) we detected 17 strange trades.

Benzinga

Covid-19 Play Pfizer Stock Nearing New Buy Point; Is It Worth Considering?

Pfizer stock may be the latest contender for your watchlist as shares set up to score a breakout from a new buy point.

Investors Business Daily

Teen COVID boosters being considered

Case numbers of COVID-19 have been increasing across the country in recent days due to infections linked to an Omicron sub-variant.

AAP

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Fosun Pharma Hopes Covid Vaccine Can Cure Its Ailing Margins

Key takeaways:

The Independent UK

Antiviral drug to be trialled in hospitalised Covid patients

Having already been approved for early-stage treatment of Covid, scientists will now assess how Paxlovid performs when administered to people hospitalised with infection

The Guardian - UK

Why the UK can’t rely on boosters to get through each new wave of Covid

The evidence suggests performance could be less predictable and effective in the future – though there are promising developments, says Danny Altmann, a professor of immunology at Imperial College London

Asharq Al-Awsat

2nd COVID Vaccine Booster Significantly Lowers Death Rate, Israeli Study Shows

Senior citizens who received a second booster of the Pfizer–BioNTech COVID-19 vaccination had a 78% lower mortality rate from the disease than those who got one only, a study from Israel showed on Sunday. The country's largest healthcare provider, Clalit Health Services, said the 40-day study included more than half…

Get all your
news in one place.

100’s of premium titles.
One news app.

Tribune News Service

COVID-19 boosters, BA.2 subvariant, treatments: 6 things we still need to keep an eye on

Coronavirus case numbers have plummeted across much of the U.S., including Texas, a promising sign that COVID-19 could finally be waning. But the pandemic is far from over, especially for older adults, people with disabilities and other vulnerable populations.

The Hindu

KTR showcases Telangana to pharma majors

Meets top leadership of Pfizer, Johnson & Johnson and GSK as part of his official tour to the US

The Independent UK

Covid vaccinations in US fall to lowest level since 2020

Public health experts say the low number of Americans receiving booster shots is an ‘unforgivable liability’

StockNews.com

3 Vaccine Stocks to Buy Following the Surge in COVID-19 Cases in China

China is battling with its worst COVID-19 outbreak since 2020. Surging cases of a new omicron variant worldwide are raising concerns that another COVID-19 wave is coming, which could drive demand for future vaccine orders. This bodes well for popular vaccine stocks Pfizer (PFE), Moderna (MRNA), and BioNTech (BNTX), and…

The Independent UK

FDA advisory panel to discuss Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

The Independent UK

FDA advisory panel to discuss additional Covid-19 boosters: What we know so far

Pfizer and Moderna seek approval for second ‘booster’ doses as White House warns US has exhausted funding to buy more shots

Benzinga

Pfizer's RSV Vaccine Candidate Receives FDA Breakthrough Therapy Tag For Prevention of RSV In Older Adults

The FDA has granted Breakthrough Therapy Designation to Pfizer Inc's (NYSE:PFE) respiratory syncytial virus (RSV) vaccine candidate (PF-06928316 or RSVpreF) to prevent lower respiratory tract disease caused by RSV in 60 years of age or older. The positive results primarily inform the FDA decision of Phase 2a study evaluating the safety, immunogenicity, and efficacy…

1 … 59 60 61 62

People

Ketanji Brown Jackson

Alexandria OcasioCortez

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.